These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28102550)

  • 1. Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement.
    Austin PC; Fine JP
    Stat Med; 2017 Apr; 36(8):1203-1209. PubMed ID: 28102550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction to the Analysis of Survival Data in the Presence of Competing Risks.
    Austin PC; Lee DS; Fine JP
    Circulation; 2016 Feb; 133(6):601-9. PubMed ID: 26858290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications.
    Varadhan R; Weiss CO; Segal JB; Wu AW; Scharfstein D; Boyd C
    Med Care; 2010 Jun; 48(6 Suppl):S96-105. PubMed ID: 20473207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considerations for analysis of time-to-event outcomes subject to competing risks in veterinary clinical studies.
    Oyama MA; Shaw PA; Ellenberg SS
    J Vet Cardiol; 2018 Jun; 20(3):143-153. PubMed ID: 29680637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kaplan-Meier Survival Analysis Overestimates the Risk of Revision Arthroplasty: A Meta-analysis.
    Lacny S; Wilson T; Clement F; Roberts DJ; Faris PD; Ghali WA; Marshall DA
    Clin Orthop Relat Res; 2015 Nov; 473(11):3431-42. PubMed ID: 25804881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis for aggregated survival data with competing risks: a parametric approach using cumulative incidence functions.
    Bonofiglio F; Beyersmann J; Schumacher M; Koller M; Schwarzer G
    Res Synth Methods; 2016 Sep; 7(3):282-93. PubMed ID: 26387882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
    Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
    Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cumulative incidence in competing risks data and competing risks regression analysis.
    Kim HT
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):559-65. PubMed ID: 17255278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competing risk bias was common in Kaplan-Meier risk estimates published in prominent medical journals.
    van Walraven C; McAlister FA
    J Clin Epidemiol; 2016 Jan; 69():170-3.e8. PubMed ID: 26232083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical issues in the analysis of adverse events in time-to-event data.
    Allignol A; Beyersmann J; Schmoor C
    Pharm Stat; 2016 Jul; 15(4):297-305. PubMed ID: 26929180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical recommendations for reporting Fine-Gray model analyses for competing risk data.
    Austin PC; Fine JP
    Stat Med; 2017 Nov; 36(27):4391-4400. PubMed ID: 28913837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dealing with competing risks: testing covariates and calculating sample size.
    Pintilie M
    Stat Med; 2002 Nov; 21(22):3317-24. PubMed ID: 12407674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A new perspective of survival data on clinical epidemiology: introduction of competitive risk model].
    Nie ZQ; Ou YQ; Qu YJ; Yuan HY; Liu XQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Aug; 38(8):1127-1131. PubMed ID: 28847068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A note on competing risks in survival data analysis.
    Satagopan JM; Ben-Porat L; Berwick M; Robson M; Kutler D; Auerbach AD
    Br J Cancer; 2004 Oct; 91(7):1229-35. PubMed ID: 15305188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplant as a competing risk in the analysis of dialysis patients.
    van Geloven N; le Cessie S; Dekker FW; Putter H
    Nephrol Dial Transplant; 2017 Apr; 32(suppl_2):ii53-ii59. PubMed ID: 28340227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competing risk bias in Kaplan-Meier risk estimates can be corrected.
    van Walraven C; Hawken S
    J Clin Epidemiol; 2016 Feb; 70():101-5. PubMed ID: 26327491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sizing clinical trials when comparing bivariate time-to-event outcomes.
    Sugimoto T; Hamasaki T; Evans SR; Sozu T
    Stat Med; 2017 Apr; 36(9):1363-1382. PubMed ID: 28120524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smooth semi-nonparametric (SNP) estimation of the cumulative incidence function.
    Duc AN; Wolbers M
    Stat Med; 2017 Aug; 36(18):2921-2934. PubMed ID: 28543626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flexible parametric modelling of the cause-specific cumulative incidence function.
    Lambert PC; Wilkes SR; Crowther MJ
    Stat Med; 2017 Apr; 36(9):1429-1446. PubMed ID: 28008649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When do we need competing risks methods for survival analysis in nephrology?
    Noordzij M; Leffondré K; van Stralen KJ; Zoccali C; Dekker FW; Jager KJ
    Nephrol Dial Transplant; 2013 Nov; 28(11):2670-7. PubMed ID: 23975843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.